Payment overview · 2025
General Payments
$127.12
8 reported records · 8 companies
Healthcare provider profile · identity verified
Sonja M. Roach, N.P.
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MOOSE LAKE, MN · NPI 1396770772
Verified facts
What the public records show
CMS Open Payments records show Sonja M. Roach, N.P. received $127.12 in general payments during 2025 across 8 reported records.
Astellas Pharma US Inc accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.56 | 17.8% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.93 | 14.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.97 | 13.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.89 | 13.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.41 | 12.1% | 1 | 2025 |
| Cepheid | Unresolved — no canonical attribution shown | $15.24 | 12.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.23 | 11.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.89 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $127.12 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| GeneXpert Normalized: genexpert |
Device | Cepheid | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 263 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 254 | 64 |
| Gabapentin | Gabapentin | 243 | 53 |
| Lisinopril | Lisinopril | 233 | 67 |
| Losartan Potassium | Losartan Potassium | 225 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 50 |
| Omeprazole | Omeprazole | 206 | 58 |
| Furosemide | Furosemide | 194 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 170 | 55 |
| Tramadol Hcl | Tramadol Hcl | 165 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 42 |
| Ozempic | Semaglutide | 107 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 97 | 21 |
| Simvastatin | Simvastatin | 97 | 33 |
| Sertraline Hcl | Sertraline Hcl | 93 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 13 |
| Celecoxib | Celecoxib | 86 | 19 |
| Metformin Hcl | Metformin Hcl | 86 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 30 |
| Eliquis | Apixaban | 76 | 14 |
| Bupropion Xl | Bupropion Hcl | 73 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 21 |
| Lorazepam | Lorazepam | 70 | 17 |
| Prednisone | Prednisone | 64 | 45 |
| Trazodone Hcl | Trazodone Hcl | 64 | 15 |
| Potassium Chloride | Potassium Chloride | 63 | 11 |
| Risperidone | Risperidone | 61 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 16 |
| Atenolol | Atenolol | 57 | 13 |
| Xarelto | Rivaroxaban | 56 | 13 |
| Pregabalin | Pregabalin | 55 | 13 |
| Metformin Hcl Er | Metformin Hcl | 54 | 14 |
| Montelukast Sodium | Montelukast Sodium | 52 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 15 |
| Warfarin Sodium | Warfarin Sodium | 50 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 17 |
| Spironolactone | Spironolactone | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Baclofen | Baclofen | 43 | 19 |
| Famotidine | Famotidine | 43 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 22 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Azithromycin | Azithromycin | 34 | 34 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Carvedilol | Carvedilol | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 17 |
| Diazepam | Diazepam | 30 | suppressed |
| Jantoven | Warfarin Sodium | 30 | 12 |
| Naproxen | Naproxen | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Cephalexin | Cephalexin | 17 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Trimethoprim | Trimethoprim | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $127.12 · 8 records | Astellas Pharma US Inc | BREZTRI, Belbuca, GeneXpert, Kerendia, REXULTI, VOQUEZNA, VRAYLAR, Veozah | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error